Peking University Fourth School of Clinical Medicine, Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Beijing, 100035, China.
National Center for Orthopaedics, Beijing, 100035, China.
J Orthop Surg Res. 2024 Oct 3;19(1):621. doi: 10.1186/s13018-024-05098-9.
This study was to analyze the clinical outcomes and prognostic factors of dedifferentiated central chondrosarcomas (DCCS) in extremities.
A retrospective study was conducted on 49 patients (27 males, 22 females) who underwent surgical treatment between January 2001 and March 2023 in our institution. All patients were diagnosed with dedifferentiated central chondrosarcomas by needle biopsy or postoperative histopathological examination. The general characters, treatment and clinical outcomes were recorded in the follow-up and all surgical-related complications that occurred were recorded in this study. Overall, these data were used to analyse the prognostic factors of DCCS.
49 patients were included in this retrospective study and there were no patients lost in the follow-up period. The median diagnosis age of all patients was 57 years old (ranging from 17 to 87) and the median follow-up time was 34 months (range, 1-289). The average tumor size was 9.6 ± 2.4 cm (3.0-15.5). Median overall survival (OS) and progression-free survival (PFS) were 34 and 23 months, respectively. The 1-year, 2-year, 5-year, and 10-year OS were 87.8% (95% CI 77.6%-98.0%), 71.4% (35/49), 28.6% (14/49) and 18.4% (9/49). And the 1-year, 2-year, 5-year, and 10-year PFS were 75.5% (95% CI 63.6%-87.4%), 49.0% (35/49), 26.5% (14/49) and 16.3% (9/49). Multiple variate analyses indicated metastasis, pathological fracture, Enneking staging and surgical margin were independent prognostic factors in extremity dedifferentiated central chondrosarcomas.
Dedifferentiated central chondrosarcomas in extremities still had a grave prognosis. Metastasis, pathological fracture, Enneking staging, and surgical margin were independent risk factors for prognosis.
IV Therapic.
本研究旨在分析四肢去分化中心性软骨肉瘤（DCCS）的临床结果和预后因素。
对 2001 年 1 月至 2023 年 3 月在我院接受手术治疗的 49 例（27 例男性，22 例女性）患者进行回顾性研究。所有患者均通过针吸活检或术后组织病理学检查诊断为去分化中心性软骨肉瘤。在随访中记录了所有患者的一般特征、治疗和临床结果，并记录了本研究中发生的所有与手术相关的并发症。总体而言，这些数据用于分析 DCCS 的预后因素。
本回顾性研究共纳入 49 例患者，随访期间无失访。所有患者的中位诊断年龄为 57 岁（17-87 岁），中位随访时间为 34 个月（1-289 个月）。肿瘤平均大小为 9.6±2.4cm（3.0-15.5cm）。中位总生存（OS）和无进展生存（PFS）分别为 34 个月和 23 个月。1 年、2 年、5 年和 10 年 OS 率分别为 87.8%（95%CI 77.6%-98.0%）、71.4%（35/49）、28.6%（14/49）和 18.4%（9/49）。1 年、2 年、5 年和 10 年 PFS 率分别为 75.5%（95%CI 63.6%-87.4%）、49.0%（35/49）、26.5%（14/49）和 16.3%（9/49）。多变量分析表明，转移、病理骨折、Enneking 分期和手术切缘是四肢去分化中心性软骨肉瘤的独立预后因素。
四肢去分化中心性软骨肉瘤预后仍较差。转移、病理骨折、Enneking 分期和手术切缘是影响预后的独立危险因素。
IV 级治疗性研究
